Baker Biotech Capital Ii (gp), Llc - Net Worth and Insider Trading
Baker Biotech Capital Ii (gp), Llc Net Worth
The estimated net worth of Baker Biotech Capital Ii (gp), Llc is at least $183 Million dollars as of 2024-11-10. Baker Biotech Capital Ii (gp), Llc is the 10% Owner of Incyte Corp and owns about 1,091,407 shares of Incyte Corp (INCY) stock worth over $91 Million. Baker Biotech Capital Ii (gp), Llc is the Director, 10% Owner of Seagen Inc and owns about 353,150 shares of Seagen Inc (SGEN) stock worth over $81 Million. Baker Biotech Capital Ii (gp), Llc is also the 10% Owner of Genomic Health Inc and owns about 181,478 shares of Genomic Health Inc (GHDX) stock worth over $12 Million. Details can be seen in Baker Biotech Capital Ii (gp), Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Baker Biotech Capital Ii (gp), Llc has not made any transactions after 2005-10-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Baker Biotech Capital Ii (gp), Llc
Baker Biotech Capital Ii (gp), Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Baker Biotech Capital Ii (gp), Llc owns 3 companies in total, including Aceragen Inc (ACGN) , Seagen Inc (SGEN) , and Incyte Corp (INCY) .
Insider Ownership Summary of Baker Biotech Capital Ii (gp), Llc
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ACGN | Aceragen Inc | 2006-03-24 | 10 percent owner |
| SGEN | Seagen Inc | 2005-05-04 | director & 10 percent owner |
| INCY | Incyte Corp | 2003-09-22 | 10 percent owner |
Baker Biotech Capital Ii (gp), Llc Latest Holdings Summary
Baker Biotech Capital Ii (gp), Llc currently owns a total of 3 stocks. Among these stocks, Baker Biotech Capital Ii (gp), Llc owns 1,091,407 shares of Incyte Corp (INCY) as of September 22, 2003, with a value of $91 Million and a weighting of 49.65%. Baker Biotech Capital Ii (gp), Llc owns 353,150 shares of Seagen Inc (SGEN) as of May 4, 2005, with a value of $81 Million and a weighting of 44.07%. Baker Biotech Capital Ii (gp), Llc also owns 181,478 shares of Genomic Health Inc (GHDX) as of October 4, 2005, with a value of $12 Million and a weighting of 6.28%.
Latest Holdings of Baker Biotech Capital Ii (gp), Llc
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| INCY | Incyte Corp | 2003-09-22 | 1,091,407 | 83.38 | 91,001,516 |
| SGEN | Seagen Inc | 2005-05-04 | 353,150 | 228.74 | 80,779,531 |
| GHDX | Genomic Health Inc | 2005-10-04 | 181,478 | 63.44 | 11,512,964 |
Holding Weightings of Baker Biotech Capital Ii (gp), Llc
Baker Biotech Capital Ii (gp), Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Baker Biotech Capital Ii (gp), Llc has made a total of 0 transactions in Incyte Corp (INCY) over the past 5 years. The most-recent trade in Incyte Corp is the acquisition of 71,100 shares on September 22, 2003, which cost Baker Biotech Capital Ii (gp), Llc around $353,367.
According to the SEC Form 4 filings, Baker Biotech Capital Ii (gp), Llc has made a total of 0 transactions in Seagen Inc (SGEN) over the past 5 years. The most-recent trade in Seagen Inc is the acquisition of 6,627 shares on May 4, 2005, which cost Baker Biotech Capital Ii (gp), Llc around $31,743.
According to the SEC Form 4 filings, Baker Biotech Capital Ii (gp), Llc has made a total of 0 transactions in Genomic Health Inc (GHDX) over the past 5 years. The most-recent trade in Genomic Health Inc is the acquisition of 38,684 shares on October 4, 2005, which cost Baker Biotech Capital Ii (gp), Llc around $464,208.
Insider Trading History of Baker Biotech Capital Ii (gp), Llc
- 1
Baker Biotech Capital Ii (gp), Llc Trading Performance
GuruFocus tracks the stock performance after each of Baker Biotech Capital Ii (gp), Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Baker Biotech Capital Ii (gp), Llc is 13.47%. GuruFocus also compares Baker Biotech Capital Ii (gp), Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Baker Biotech Capital Ii (gp), Llc within 3 months outperforms 9 times out of 11 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Baker Biotech Capital Ii (gp), Llc's insider trading performs compared to the benchmark.
Performance of Baker Biotech Capital Ii (gp), Llc
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.97 | | | | | |
| Relative Return to S&P 500(%) | 0.69 | | | | | |
Baker Biotech Capital Ii (gp), Llc Ownership Network
Ownership Network List of Baker Biotech Capital Ii (gp), Llc
Ownership Network Relation of Baker Biotech Capital Ii (gp), Llc
Baker Biotech Capital Ii (gp), Llc Owned Company Details
What does Aceragen Inc do?
Who are the key executives at Aceragen Inc?
Baker Biotech Capital Ii (gp), Llc is the 10 percent owner of Aceragen Inc. Other key executives at Aceragen Inc include director & President & CEO Vincent Milano , director & 10 percent owner Pillar Invest Corp , and 10 percent owner Atul Chopra .
Aceragen Inc (ACGN) Insider Trades Summary
Over the past 18 months, Baker Biotech Capital Ii (gp), Llc made no insider transaction in Aceragen Inc (ACGN). Other recent insider transactions involving Aceragen Inc (ACGN) include a net sale of 264,324 shares made by Atul Chopra , a net purchase of 21,147 shares made by Pillar Invest Corp , and a net sale of 3,283 shares made by Vincent Milano .
In summary, during the past 3 months, insiders sold 0 shares of Aceragen Inc (ACGN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 273,476 shares of Aceragen Inc (ACGN) were sold and 26,965 shares were bought by its insiders, resulting in a net sale of 246,511 shares.
Aceragen Inc (ACGN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aceragen Inc Insider Transactions
Baker Biotech Capital Ii (gp), Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Baker Biotech Capital Ii (gp), Llc. You might contact Baker Biotech Capital Ii (gp), Llc via mailing address: 667 Madison Ave 17th Floor, New York Ny 10021.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
